Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.70−0.06 (-1.26%)
Close on Nov 17, 2026Market cap $290.66MP/E –Yield –
Kyverna Therapeutics cash
Cash and short-term investments held at the end of each period.
Kyverna Therapeutics's cash was $170.60M at Sep 30, 2026. For fiscal 2025 it was $279.30M, down 2.3% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $279.30M | -2.3% |
| FY2024 | Dec 31, 2024 | $286.00M | +397.0% |
| FY2023 | Dec 31, 2023 | $57.54M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $170.60M | -0.3% |
| Q2 FY2026 | Jun 30, 2026 | $199.40M | -5.8% |
| Q1 FY2026 | Mar 31, 2026 | $236.40M | -2.6% |
| Q4 FY2025 | Dec 31, 2025 | $279.30M | -2.3% |
| Q3 FY2025 | Sep 30, 2025 | $171.10M | -46.8% |
| Q2 FY2025 | Jun 30, 2025 | $211.70M | -38.9% |
| Q1 FY2025 | Mar 31, 2025 | $242.60M | -34.4% |
| Q4 FY2024 | Dec 31, 2024 | $286.00M | +397.0% |
| Q3 FY2024 | Sep 30, 2024 | $321.60M | +1300.3% |
| Q2 FY2024 | Jun 30, 2024 | $346.20M | +548.0% |
| Q1 FY2024 | Mar 31, 2024 | $369.80M | +829.5% |
| Q4 FY2023 | Dec 31, 2023 | $57.54M | – |
| Q3 FY2023 | Sep 30, 2023 | $22.97M | – |
| Q2 FY2023 | Jun 30, 2023 | $53.43M | – |
| Q1 FY2023 | Mar 31, 2023 | $39.79M | – |
See a number that looks wrong?